Complement factor H binds to denatured rather than to native pentameric C-reactive protein.
Binding of the complement regulatory protein, factor H, to C-reactive protein has been reported and implicated as the biological basis for association of the H402 polymorphic variant of factor H with macular degeneration. Published studies utilize solid-phase or fluid-phase binding assays to show that the factor H Y402 variant binds C-reactive protein more strongly than H402. Diminished binding of H402 variant to C-reactive protein in retinal drusen is posited to permit increased complement activation, driving inflammation and pathology. We used well validated native human C-reactive protein and pure factor H Y402H variants to test interactions. When factor H variants were incubated with C-reactive protein in the fluid phase at physiological concentrations, no association occurred. When C-reactive protein was immobilized on plastic, either non-specifically by adsorption in the presence of Ca(2+) to maintain its native fold and pentameric subunit assembly or by specific Ca(2+)-dependent binding to immobilized natural ligands, no specific binding of either factor H variant from the fluid phase was observed. In contrast, both factor H variants reproducibly bound to C-reactive protein immobilized in the absence of Ca(2+), conditions that destabilize the native fold and pentameric assembly. Both factor H variants strongly bound C-reactive protein that was denatured by heat treatment before immobilization, confirming interaction with denatured but not native C-reactive protein. We conclude that the reported binding of factor H to C-reactive protein results from denaturation of the C-reactive protein during immobilization. Differential binding to C-reactive protein, thus, does not explain association of the Y402H polymorphism with macular degeneration.
Hakobyan
Svetlana
S
Department of Medical Biochemistry and Immunology and Pharmacology, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.
Harris
Claire L
CL
van den Berg
Carmen W
CW
Fernandez-Alonso
Maria Carmen
MC
de Jorge
Elena Goicoechea
EG
de Cordoba
Santiago Rodriguez
SR
Rivas
German
G
Mangione
Palma
P
Pepys
Mark B
MB
Morgan
B Paul
BP
D019943:Amino Acid Substitution; D001665:Binding Sites / Q000235:genetics; D002097:C-Reactive Protein / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D002118:Calcium / Q000737:chemistry / Q000378:metabolism; D017242:Complement Factor H / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008268:Macular Degeneration; D011110:Polymorphism, Genetic; D011485:Protein Binding / Q000235:genetics; D011489:Protein Denaturation / Q000235:genetics; D017510:Protein Folding; D020836:Protein Structure, Quaternary / Q000235:genetics
D017242:Complement Factor H; D002097:C-Reactive Protein; D002118:Calcium
J Clin Invest. 1993 Apr;91(4):1351-7
8473487
Mol Immunol. 1987 May;24(5):531-41
2443837
Biochem Soc Trans. 2002 Nov;30(Pt 6):971-8
12440956
Immunology. 2007 May;121(1):40-50
17244159
Mol Neurobiol. 2002 Feb;25(1):1-17
11890454
J Exp Med. 2007 Oct 1;204(10):2277-83
17893204
Immunopharmacology. 1999 May;42(1-3):23-30
10408362
J Immunol. 2007 Mar 15;178(6):3831-6
17339482
Anal Biochem. 2004 Mar 15;326(2):234-56
15003564
World Health Organ Tech Rep Ser. 1987;760:1-203
3124356
J Immunol. 1999 Oct 1;163(7):3957-62
10490997
Science. 2005 Apr 15;308(5720):419-21
15761120
Structure. 1999 Feb 15;7(2):169-77
10368284
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17456-61
17079491
Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227-32
15870199
Mol Immunol. 2007 Jul;44(13):3398-406
17399790
Science. 2005 Apr 15;308(5720):385-9
15761122
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1104-8
11923252
Nature. 2006 Apr 27;440(7088):1217-21
16642000
Mol Immunol. 2004 Jun;41(4):355-67
15163532
Biochemistry. 2007 Jul 17;46(28):8451-61
17580967
Biochemistry. 1989 Dec 12;28(25):9840-8
2692716
J Biol Chem. 2005 Jan 28;280(4):2569-78
15536079
J Immunol. 1989 Jul 1;143(1):221-8
2471736
Eur J Immunol. 2003 Apr;33(4):962-9
12672062
J Biol Chem. 2006 Aug 25;281(34):24713-20
16787919
J Immunol. 1984 Aug;133(2):882-5
6234363
J Heart Lung Transplant. 2007 Jul;26(7):705-13
17613401
J Clin Lab Immunol. 1992;37(4):147-62
1285067
Immunology. 1982 Jan;45(1):55-70
7056568
Mol Immunol. 1983 Nov;20(11):1165-75
6656768
Immunology. 2007 Mar;120(3):404-11
17163961
Exp Eye Res. 2001 Dec;73(6):887-96
11846519
J Immunol Methods. 1989 Aug 15;122(1):105-13
2760472
Science. 2005 Apr 15;308(5720):421-4
15761121
J Immunol. 1974 Jul;113(1):9-17
4208926
Scand J Immunol. 2006 Mar;63(3):155-68
16499568
J Biol Chem. 2007 Apr 13;282(15):10894-900
17293598
Nat Struct Biol. 1996 Apr;3(4):346-54
8599761
J Biol Chem. 2007 Jun 29;282(26):18960-8
17360715
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jun 1;63(Pt 6):480-3
17554167
Invest Ophthalmol Vis Sci. 2008 May;49(5):1763-70
18263814
J Immunol. 2006 Feb 1;176(3):1305-10
16424154
Mol Microbiol. 2008 Nov;70(3):583-94
18627465